BioCardia Inc (BCDA)
2.135
+0.14
(+7.29%)
USD |
NASDAQ |
Nov 21, 16:00
2.18
+0.04
(+2.11%)
After-Hours: 07:55
BioCardia Enterprise Value: 4.858M for Nov. 21, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 21, 2024 | 4.858M |
| November 20, 2024 | 4.193M |
| November 19, 2024 | 4.376M |
| November 18, 2024 | 4.468M |
| November 15, 2024 | 3.551M |
| November 14, 2024 | 4.307M |
| November 13, 2024 | 5.843M |
| November 12, 2024 | 6.072M |
| November 11, 2024 | 5.614M |
| November 08, 2024 | 5.430M |
| November 07, 2024 | 5.915M |
| November 06, 2024 | 6.072M |
| November 05, 2024 | 6.210M |
| November 04, 2024 | 5.837M |
| November 01, 2024 | 5.882M |
| October 31, 2024 | 5.611M |
| October 30, 2024 | 5.792M |
| October 29, 2024 | 6.018M |
| October 28, 2024 | 6.968M |
| October 25, 2024 | 6.018M |
| October 24, 2024 | 5.927M |
| October 23, 2024 | 6.289M |
| October 22, 2024 | 6.832M |
| October 21, 2024 | 7.194M |
| October 18, 2024 | 7.239M |
| Date | Value |
|---|---|
| October 17, 2024 | 7.058M |
| October 16, 2024 | 6.990M |
| October 15, 2024 | 6.108M |
| October 14, 2024 | 6.787M |
| October 11, 2024 | 7.058M |
| October 10, 2024 | 7.284M |
| October 09, 2024 | 7.194M |
| October 08, 2024 | 7.058M |
| October 07, 2024 | 7.239M |
| October 04, 2024 | 7.466M |
| October 03, 2024 | 7.782M |
| October 02, 2024 | 7.556M |
| October 01, 2024 | 8.551M |
| September 30, 2024 | 9.185M |
| September 27, 2024 | 8.875M |
| September 26, 2024 | 8.244M |
| September 25, 2024 | 7.579M |
| September 24, 2024 | 7.019M |
| September 23, 2024 | 7.229M |
| September 20, 2024 | 7.474M |
| September 19, 2024 | 9.015M |
| September 18, 2024 | 9.365M |
| September 17, 2024 | 8.349M |
| September 16, 2024 | 8.454M |
| September 13, 2024 | 8.980M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
3.252M
Minimum
Aug 28 2024
76.39M
Maximum
Dec 15 2020
23.79M
Average
21.72M
Median
Feb 24 2022
Enterprise Value Benchmarks
| Alnylam Pharmaceuticals Inc | 30.08B |
| The Cooper Companies Inc | 22.42B |
| Theriva Biologics Inc | -12.68M |
| Zevra Therapeutics Inc | 456.85M |
| Instil Bio Inc | 123.40M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -1.737M |
| Total Expenses (Quarterly) | 1.756M |
| EPS Diluted (Quarterly) | -0.61 |
| Earnings Yield | -197.7% |
| Normalized Earnings Yield | -252.93 |